Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00311
|
|||||
| Drug Name |
Ambrisentan
|
|||||
| Synonyms |
(+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid; Ambrisentan [INN]; BSF 208075; BSF-208075; BSF208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; Gilead brand of ambrisentan; LU 208075; LU-208075; LU208075; Letairis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pulmonary arterial hypertension [ICD11: BB01.0] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C22H22N2O4
|
|||||
| Canonical SMILES |
CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
|
|||||
| InChI |
InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
|
|||||
| InChIKey |
OUJTZYPIHDYQMC-LJQANCHMSA-N
|
|||||
| CAS Number |
CAS 177036-94-1
|
|||||
| Pharmaceutical Properties | Molecular Weight | 378.4 | Topological Polar Surface Area | 81.5 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
3.8
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103307060
, 104035299
, 114788055
, 118855302
, 12015371
, 126616865
, 126651844
, 131302629
, 134338642
, 135692418
, 137237404
, 139988399
, 143497715
, 144205520
, 14779987
, 152133959
, 152238501
, 152258462
, 160647297
, 160826914
, 162011508
, 162172038
, 163093066
, 163387054
, 164824132
, 170465143
, 17194924
, 174007223
, 175267375
, 175426501
, 178100778
, 179116973
, 185986582
, 187071933
, 196107821
, 198977886
, 198991664
, 204430246
, 211534802
, 223375980
, 223532574
, 223704800
, 224518792
, 226395806
, 43529863
, 50551569
, 51091419
, 53787770
, 57371956
, 93309673
|
|||||
| ChEBI ID |
CHEBI:135949
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Ambrisentan was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.